BBS10 Antibodies

Santa Cruz Biotechnology delivers a wide array of BBS10 monoclonal antibodies for research in understanding Bardet-Biedl Syndrome and its underlying mechanisms. BBS10 monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). BBS10 plays a vital role in cilia function and is associated with the regulation of cellular signaling pathways. Mutations in the BBS10 gene can lead to Bardet-Biedl Syndrome, a genetic disorder characterized by obesity, retinal degeneration, and renal abnormalities. Understanding BBS10's function is essential for elucidating the pathophysiology of this syndrome and developing potential therapeutic strategies. Research into BBS10 continues to reveal new insights about its role in cellular processes and disease development. Investigating BBS10's molecular interactions provides valuable information about ciliary function and its impact on human health. Current studies focus on understanding how BBS10 mutations affect cellular pathways and contribute to disease progression. Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing scientific understanding of Bardet-Biedl Syndrome and its potential treatments.